Starting next year, Amgen Inc. will list Repatha for $5,850 a year for all insurers. It rolled out at that price last year, but still supplied the treatment at the original price of more than $14,000 in some cases. "Amgen Posts Stronger-than-Expected 3Q Results -- Earnings Review" at 16:18 p.m. ET, incorrectly stated that $5,850 was 60% lower than the current price.

(END) Dow Jones Newswires

October 29, 2019 18:36 ET (22:36 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Amgen Charts.